Viventia and ESBATech AG enter collaboration to enhance antibodies
Toronto and Zurich. Viventia Biotech Inc. Toronto, Canada and ESBATech AG Zurich, Switzerland, announced that they have entered into a license agreement and research collaboration. The goal of the collaboration is to investigate whether ESBATech's unique antibody stabilization and Expression technology can enhance the characteristics of certain antibodies discovered through Viventia's proprietary antibody discovery and screening platforms Hybridomics(TM) and ImmunoMine(TM), with a view to the development of drug candidates in the field of oncology.
Under the terms of the agreement ESBATech will receive an upfront payment and research funding. At the end of the collaboration, Viventia has the option to license the ESBATech technology for clinical development, with milestone payments and royalties due to ESBATech.
As part of the research collaboration, ESBATech will utilize its proprietary technologies to investigate whether these technologies have the potential to enhance the stability, binding and yield of certain recombinant antibody fragments engineered by Viventia. Dr. Nick Glover, President and CEO, Viventia Biotech said, "Viventia seeks partners, such as ESBATech, who can complement our own discovery platforms and help us deliver on our goal of creating safer and more potent therapeutics for the fight against cancer. I look forward to a mutually beneficial collaboration with them."
ESBATech AG is a drug discovery and development company employing proprietary, fully human antibody fragment technology for the development of therapeutic applications in the fields of Alzheimer's disease, respiratory infections and oncology. Dr. Dominik Escher, CEO, ESBATech commented, "ESBATech is very pleased with the recognition of the potential of its technology by Viventia. We are pleased to have the opportunity to work in collaboration with Viventia and look forward to helping Viventia advance its strategy of developing highly specific targeted therapeutics."
Viventia Biotech Inc. is developing innovative therapeutic products based upon the human immune response to cancer. Through its discovery platform, Hybridomics , target identification platform UnLock(TM), and its screening platform, ImmunoMine , the Company is focused on developing "Totally Human" monoclonal antibodies as Armed Antibodies(TM) to fight multiple forms of cancer.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
